Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 February 2021 Photo UFS photo archive
The National Control Laboratory for Biological Products (NCL) Building.

There can be no compromise when it comes to the quality of medicines made available to the public.

The UFS-based National Control Laboratory for Biological Products (NCL) is a full member of the international WHO-National Control Laboratory Network for Biologicals and one of 12 laboratories worldwide contracted to perform vaccine testing for the World Health Organisation (WHO). The NCL is also the only vaccine-testing laboratory in the country that performs the final quality-control testing of all human vaccine batches marketed in South Africa on behalf of the South African Health Products Regulatory Authority (SAHPRA).

In its role as a vaccine-testing laboratory for the WHO, the NCL helps to ensure that the vaccines purchased through the WHO prequalification programme for international distribution to resource-limited countries, meet the high standards of quality, safety, and efficiency. 

International testing standards

The laboratory received the status of a pharmaceutical testing laboratory after the South African Accreditation System (SANAS) endorsed its quality-management systems as of a high standard according to the International Standards Organisation’s requirements.

With its international testing standards, the NCL must ensure that all its operations – from the way documents are compiled and stored, to the maintenance of equipment and infrastructure, as well as staff competency – are performed according to international guidelines.

The laboratory has all the quality systems in place to ensure high-quality test results. The certificate of Good Manufacturing Compliance received in 2019 indicates that laboratory testing is on the expected level for any pharmaceutical testing laboratory and manufacturer. This certification is very strict and means that the NCL complies with exceptionally strict standards for pharmaceutical labs anywhere in the world. The certification offers the South African Health Products Regulatory Authority, the WHO, and other national control laboratories around the world the confidence that the test results from the NCL can be trusted.

Licensed as pharmaceutical manufacturer

The laboratory is also licensed as a pharmaceutical manufacturer. Although the lab does not manufacture, it needs to comply with manufacturing standards. It is rare for a pharmaceutical testing laboratory (such as the NCL) outside of a manufacturing context to qualify for both certifications.

News Archive

Construction work on new residences begins
2012-02-24

 

From left are: Richard Chemaly, SRC President; Mr Quintin Koetaan; Prof. Nicky Morgan, Vice-Rector: Operations and Mr Pura Mgolombane, Assistant Dean: Student Affairs, at the sod turning ceremony.    
Photo: Johan Roux  
24 February 2012

Construction of two new residences on our Bloemfontein Campus will begin soon. Some 500 students will be accommodated in the residences, with the first students able to move in from January 2013.   

The premises where the residences will be built were recently handed over to the contractors.

Mr Rudi Buys, Dean of Student Affairs, says that the design of the residences follow global trends in student accommodation, but are adapted to local needs and student communities. The new residences will provide more study and tutoring spaces, also with more open space for diverse students to socialise. The residences will function together as a Student Life College.

Mr Quintin Koetaan, Director: Housing and Residence Affairs, says the new residences will house both junior and senior students. Residences will co-ed, with men and women housed in separate and secure passages.
 
The planned construction of student accommodation includes five new residences – four on the Bloemfontein Campus that will provide 1000 beds and one on the Qwaqwa Campus with 250 beds. This will provide for the increasing need for student accommodation. The project will be completed in two phases. Phase one commenced in Bloemfontein on 21 February 2012.


 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept